Company Overview
| Stock Name | GHW Intl |
|---|---|
| Stock Code | 09933 |
| Company Full Name | To be extracted |
| Industry | Industrial Goods |
| Principal Activities | 本集團是一家综合化学品服务市场的应用化学中间体供应商,主要从事生产及销售自产化学品以及销售位于中国、东南亚地区、欧洲及美国的第三方制造商生产的化学品,业务包括聚氨酯材料、动物营养化学品、精细化学品及医药产品及中间体四大分部。 |
| Listing Date | 2020-01-21 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 南京市奧體大街69號新城科技園6棟 |
| Business Address (Hong Kong) | 香港上環永樂街93-103號協成行上環中心1604室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.goldenhighway.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 0.51 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 4,000 shares |
| Entry Threshold | HK$ 2,040 |
| Par Value | RMB 0.01 / shares |
| Offer Period | 2019-12-31 to 2020-01-10 |
| Global Offering Shares | 250,000,000 shares |
| HK Public Offer Shares (Initial) | 25,000,000 shares (10.0%) |
| Public Offer Lots (Initial) | 6,250lots (Pool A3,125lots,Pool B3,125lots) |
| International Placing Shares (Initial) | 225,000,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,000,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 127,500,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 4,000 | HK$ 2,040 |
| 2 lots | 8,000 | HK$ 4,080 |
| 3 lots | 12,000 | HK$ 6,120 |
| 4 lots | 16,000 | HK$ 8,160 |
| 5 lots | 20,000 | HK$ 10,200 |
| 6 lots | 24,000 | HK$ 12,240 |
| 7 lots | 28,000 | HK$ 14,280 |
| 8 lots | 32,000 | HK$ 16,320 |
| 9 lots | 36,000 | HK$ 18,360 |
| 10 lots | 40,000 | HK$ 20,400 |
| 15 lots | 60,000 | HK$ 30,600 |
| 20 lots | 80,000 | HK$ 40,800 |
| 25 lots | 100,000 | HK$ 51,000 |
| 30 lots | 120,000 | HK$ 61,200 |
| 35 lots | 140,000 | HK$ 71,400 |
| 40 lots | 160,000 | HK$ 81,600 |
| 45 lots | 180,000 | HK$ 91,800 |
| 50 lots | 200,000 | HK$ 102,000 |
| 75 lots | 300,000 | HK$ 153,000 |
| 100 lots | 400,000 | HK$ 204,000 |
| 125 lots | 500,000 | HK$ 255,000 |
| 150 lots | 600,000 | HK$ 306,000 |
| 175 lots | 700,000 | HK$ 357,000 |
| 200 lots | 800,000 | HK$ 408,000 |
| 225 lots | 900,000 | HK$ 459,000 |
| 250 lots | 1,000,000 | HK$ 510,000 |
| 500 lots | 2,000,000 | HK$ 1,020,000 |
| 750 lots | 3,000,000 | HK$ 1,530,000 |
| 1,250 lots | 5,000,000 | HK$ 2,550,000 |
| 2,000 lots | 8,000,000 | HK$ 4,080,000 |
| 2,250 lots | 9,000,000 | HK$ 4,590,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 2,500 lots | 10,000,000 | HK$ 5,100,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 1.67B |
| Est. Threshold | HK$ 9.73B |
| Analysis Result | HK market cap below threshold, need +481% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 580,000,000 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣74.3百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 48,700,000 |
| Listing Expenses / Funds Raised | ~38.2% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2016 | 2017 | 2018 |
|---|---|---|---|
| Revenue | 1,606,829 | 2,179,049 | 2,152,946 |
| Cost of sales | -1,441,863 | -1,861,438 | -1,843,384 |
| Gross profit | 164,966 | 317,611 | 309,562 |
| Other income and gains, net | 8,552 | 7,921 | 3,731 |
| Selling and distribution expenses | -67,661 | -79,196 | -83,502 |
| Administrative expenses | -52,227 | -84,232 | -77,690 |
| Operating profit | 30,371 | 104,747 | 102,083 |
| Net finance costs | -9,160 | -10,685 | -10,831 |
| Profit before tax | 21,211 | 94,062 | 91,252 |
| Income tax expense | -454 | -14,631 | -16,995 |
| Profit for the year | 20,757 | 79,431 | 74,257 |
| Profit attributable to owners | 19,148 | 78,223 | 74,257 |
Balance Sheet
| Item | 2016 | 2017 | 2018 | 2019-06 |
|---|---|---|---|---|
| Cash and cash equivalents | 40,877 | 34,620 | 30,261 | |
| Trade and bills receivables | 131,581 | 140,998 | 164,174 | |
| Inventories | 100,388 | 152,471 | 164,601 | |
| Total current assets | 341,245 | 413,843 | 442,431 | |
| Total assets | 516,566 | 592,837 | 648,758 | |
| Total current liabilities | 421,525 | 493,818 | 554,297 | |
| Total liabilities | 452,009 | 500,372 | 559,764 | |
| Total equity | 64,557 | 92,465 | 88,994 | |
| Equity attributable to owners | 61,248 | 92,465 | 88,994 | |
| Interest-bearing borrowings | 159,513 | 178,866 | 198,357 | 324,328 |
Cash Flow Statement
| Item | 2016 | 2017 | 2018 | 2019-06 |
|---|---|---|---|---|
| Net cash from operating activities | 69,024 | 54,351 | 19,801 | |
| Net cash from investing activities | -43,488 | -53,302 | -19,351 | |
| Net cash from financing activities | -10,571 | -8,633 | -4,048 | |
| Net increase in cash | 14,965 | -7,584 | -3,598 | |
| Depreciation of PP&E | 12,503 | 15,535 | 16,109 | 8,912 |
| Depreciation of right-of-use assets | 0 | 0 | 0 | 2,499 |
| Purchase of PP&E | -50,108 | -45,043 | -23,270 | -27,688 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 0.35 |
|---|---|
| First Day Open | HK$ 0.44 |
| First Day Change | -31.37% |
| First Day Volume | 100384000.0 |
| First Day Turnover | 41692300.0 |
| Use of Proceeds | 1、約17.2%或12.8百萬港元將用于成立初期的新生產廠房;
2、約60.4%或45.1百萬港元將用于在新生產廠房建設生產三甲胺的生產設施;
3、約10.2%或7.6百萬港元將用于在新生產廠房建設小批生產不同類型醫藥中間體)的試驗廠房;
4、約2.2%或1.6百萬港元將用于我們的新醫藥產品鹽酸莫西沙星片的研發過程;
5、約0.8%或0.6百萬港元將用于采購硬件及軟件為我們現有的財務及會計管理系統)升級;
6、約9.2%或6.9百萬港元將用作營運資金及其他一般企業用途。 |
Underwriting Syndicate
Sole Sponsor (1)
Fortune Financial Capital Limited CE ARN695
Overall Coordinators (2)
Joint Bookrunners (5)
Joint Lead Managers (9)
FORTUNE (HK) SECURITIES LIMITED CE AHQ488
HEAD & SHOULDERS SECURITIES LIMITED CE AFS455
I WIN SECURITIES LIMITED CE BJB315
SPDB International Capital Limited CE BFZ375
FIRST SHANGHAI SECURITIES LIMITED CE ABV488
FTFT International Securities and Futures Limited CE ATR516
China New Securities Limited CE BGB265
Standard Perpetual Securities Limited CE BHU509
Livermore Holdings Limited CE BJN764
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 尹燕濱 | — |
| Company Secretary | 胡穎豪 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 控股股东尹燕濱及吳海嶺女士透过Commonwealth B Limited及Commonwealth Happy Elephant Limited等持有股份,緊隨全球發售及資本化發行完成後合計持有約55.31%股份。 |
|---|




